AnaptysBio (NASDAQ:ANAB) CFO Sells $86,069.88 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) CFO Dennis Mulroy sold 1,908 shares of the business’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $45.11, for a total transaction of $86,069.88. Following the completion of the sale, the chief financial officer directly owned 17,667 shares of the company’s stock, valued at approximately $796,958.37. This trade represents a 9.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Dennis Mulroy also recently made the following trade(s):

• On Thursday, January 8th, Dennis Mulroy sold 2,515 shares of AnaptysBio stock. The stock was sold at an average price of $44.71, for a total transaction of $112,445.65.
• On Monday, January 5th, Dennis Mulroy sold 3,363 shares of AnaptysBio stock. The shares were sold at an average price of $43.26, for a total transaction of $145,483.38.
• On Monday, December 22nd, Dennis Mulroy sold 10,000 shares of AnaptysBio stock. The shares were sold at an average price of $50.00, for a total value of $500,000.00.
• On Tuesday, December 16th, Dennis Mulroy sold 15,725 shares of AnaptysBio stock. The stock was sold at an average price of $44.85, for a total value of $705,266.25.

AnaptysBio Stock Up 2.0%

Shares of NASDAQ ANAB opened at $44.67 on Friday. AnaptysBio, Inc. has a twelve month low of $12.21 and a twelve month high of $52.47. The firm has a market cap of $1.24 billion, a PE ratio of -15.84 and a beta of 0.32. The business has a fifty day simple moving average of $42.62 and a two-hundred day simple moving average of $31.51.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $1.58. The business had revenue of $76.32 million for the quarter, compared to the consensus estimate of $15.83 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%. On average, research analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio declared that its Board of Directors has initiated a stock buyback program on Friday, November 21st that allows the company to buyback $100.00 million in outstanding shares. This buyback authorization allows the biotechnology company to repurchase up to 9.6% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Institutional Trading of AnaptysBio

Hedge funds and other institutional investors have recently made changes to their positions in the business. Assenagon Asset Management S.A. boosted its position in shares of AnaptysBio by 4,852.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock worth $25,719,000 after purchasing an additional 822,975 shares in the last quarter. Woodline Partners LP raised its stake in AnaptysBio by 63.1% in the first quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock valued at $14,705,000 after buying an additional 305,950 shares during the last quarter. 683 Capital Management LLC raised its stake in AnaptysBio by 155.6% in the second quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock valued at $11,100,000 after buying an additional 304,373 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in AnaptysBio by 2.7% in the third quarter. Jacobs Levy Equity Management Inc. now owns 378,452 shares of the biotechnology company’s stock worth $11,588,000 after acquiring an additional 10,005 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its stake in shares of AnaptysBio by 145.6% during the third quarter. Arrowstreet Capital Limited Partnership now owns 370,458 shares of the biotechnology company’s stock worth $11,343,000 after acquiring an additional 219,648 shares during the last quarter.

Wall Street Analyst Weigh In

ANAB has been the subject of several research reports. UBS Group started coverage on shares of AnaptysBio in a research report on Wednesday. They issued a “buy” rating and a $70.00 price target for the company. Guggenheim restated a “buy” rating on shares of AnaptysBio in a report on Thursday, December 18th. Barclays dropped their target price on AnaptysBio from $70.00 to $55.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 17th. Stifel Nicolaus reduced their price target on AnaptysBio from $80.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, December 11th. Finally, Wells Fargo & Company raised their price objective on AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, AnaptysBio currently has a consensus rating of “Moderate Buy” and an average price target of $60.40.

Key Headlines Impacting AnaptysBio

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: UBS upgraded ANAB to a “strong‑buy” and raised its price target to $70, increasing visible upside and likely attracting retail and institutional flows. UBS upgrade / coverage note
• Positive Sentiment: Anaptys filed a partial motion to dismiss Tesaro’s anticipatory‑breach claim in its Delaware Chancery Court dispute with GSK/Tesaro over Jemperli royalties; a favorable court outcome would lower potential royalty liabilities and legal uncertainty around future cash flows. Reuters: partial dismissal filing
• Positive Sentiment: Company has an active $100M buyback authorization (announced November), which supports shares by reducing float and signals board confidence in valuation.
• Neutral Sentiment: Several institutional investors have recently increased positions substantially (Assenagon, Woodline, 683 Capital, Arrowstreet), which can support liquidity but may not move price immediately.
• Negative Sentiment: Significant insider selling disclosed this week: CEO Daniel Faga sold ~9,202 shares (~$662k) and CFO Dennis Mulroy sold 1,908 shares (and has sold other blocks recently); additional insider dispositions by other executives were also filed — these sales can create near‑term selling pressure or raise questions about insider timing despite large remaining holdings. CEO sale article CFO Form 4
• Negative Sentiment: Clustered insider sales (multiple executives and directors) increase the visible supply and may blunt momentum from upgrades or legal progress until filings show stabilization. SEC Form 4 filings (insider sales)

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.